Notes on Category Selection

Original research on HIV and related infections, COVID-19, and mpox may be submitted for consideration. The Scientific Program Committee may, from time to time, add specific emerging infections to the research presented at CROI. These infections are those that impact the lives and health of people with or at risk of HIV, such as viral hepatitis, tuberculosis, and mpox, or those that have immediate global threats to health, such as COVID-19. 

Before selecting a category, please review the category description and the following guidelines to ensure that appropriate review team reviews your abstract:   

  • All studies of infants, children, or adolescents should be submitted to category (P)Childhood and Adolescent HIV, SARS-CoV-2, or Mpox Virus 
  • All resistance studies and trials should be submitted to category (H) Resistance of HIV or SARS-CoV-2 to Small Molecules and Antibodies in Adults 
  • All studies of hepatitis, including hepatitis A, B, C, D, and E in monoinfection or HIV coinfection and liver complications (eg, NASH and NAFLD), should be submitted to category(I) Hepatitis Viruses and Liver Complications in Adults 
  • Diagnostics: Studies of new technologies related to HIV drug resistance, complications, tuberculosis, other opportunistic infections, hepatitis, or malignancies should be submitted to those specific categories. Studies applying new diagnostics in populations should be submitted to category(R) Testing for HIV, COVID-19, and Mpox in Adults: New Tests, Population Studies, and Scale-Up  
  • Population and Cost Modeling: Studies that include research on demography, population impact, modeling, and cost-effectiveness should be submitted to the relevant topical category. Reviewers of these abstracts will include individuals with modeling expertise 
  • Behavioral or relevant social sciences studies should be submitted to the respective categories, including (U) Implementation and Scale-Up of Prevention and Treatment for HIV, and Impact of COVID-19 and Mpox on HIV-Related Programs; (G)  Antiviral Therapy: Pre-Clinical Data, Randomized Trials, Efficacy, and Effectiveness Studies in HIV or SARS-CoV-2 or Mpox Virus in Adults; and (S) Prevention of HIV, COVID-19, and Mpox in Adults 
Letter
Category Title
Description
Basic Science
Virology of HIV, SARS-CoV-2, or Mpox Virus   Studies related to basic HIV virology, including studies of viral replication in vitro, host restriction factors, viral life cycle, entry, tropism, viral phenotypes, and genotypes. This category includes studies of the virology of SARS-CoV-2 and the mpox virus.  
Pathogenesis of HIV, SARS-CoV-2, or Mpox Virus: Human Studies and Animal Models Studies of factors influencing disease outcome in human and animal models for HIV including viral-host interactions, immune activation, host cell targets, cell compartments for infection, genotype (viral and host), and disease. This category includes studies addressing similar issues for SARS-CoV-2 and the mpox virus.  
Host Immune Responses, Vaccines, and Immunotherapies: HIV, SARS-CoV-2, or Mpox Virus   Studies of immune responses (B-cell, T-cell, and innate) to HIV infection and vaccines, and immunomodulatory therapeutic interventions (eg, cytokine interventions, passive antibody treatment). This category includes studies addressing similar areas for SARS-CoV-2 and the mpox virus. 
HIV Reservoirs, Latency, and Curative Strategies Including Therapeutic Vaccines and Gene Therapy  Studies of all aspects of HIV reservoirs, latency, and approaches to cure, including human and animal studies related to these topics.  
Neuropathogenesis and Neurologic Complications of HIV and SARS-CoV-2 Infection and Neurologic Complications of HIV in Adults   Studies of all aspects of HIV neuropathogenesis including neuroimmunity, neurodegeneration, virology of central nervous system (CNS) infection, CNS complications of systemic infection (including neurocognitive dysfunction and associated factors or responses), cerebrovascular complications, and biomarkers (including neuroimaging). This category includes similar studies related neuropathogenesis and neurologic complications of SARS-CoV-2. 
Clinical
F Clinical Pharmacology in Adults Studies of pharmacokinetics and pharmacodynamics (PK/PD) of small and large molecule drugs in animal models and adult humans, including drug absorption, distribution, metabolism, and excretion, novel dosing regimens, drug interactions, simulation and modeling, and novel uses of objective drug adherence and exposure metrics. 

Studies of infants, children, or adolescents should be submitted to category (P). 

G Antiviral Therapy: Pre-Clinical Data, Randomized Trials, Efficacy, and Effectiveness Studies in HIV or SARS-CoV-2 or Mpox Virus in Adults  Studies of antiviral agents and combinations, including virus-directed monoclonal antibodies and new antiviral agents (including pre-clinical data, interventional trials, and observational and cohort studies) where the focus is on antiviral therapy and antiviral treatment strategies for HIV or SARS-CoV-2 or mpox virus. Studies of patient and provider attitudes about different antiviral treatment options and studies of adherence should be submitted here. 

Studies that focus on resistance should be submitted to category (H). 

H Resistance of HIV or SARS-CoV-2 to Small Molecules and Antibodies in Adults  Studies of molecular mechanisms, pathogenesis, clinical implications, epidemiology, and diagnostics around resistance. 

Studies of infants, children, or adolescents should be submitted to category (P). 

I Hepatitis Viruses and Liver Complications in Adults Studies of diagnostics, epidemiology, pathogenesis, and therapy for hepatitis viruses and liver complications of HIV or SARS-CoV-2 in adults. 

Studies of infants, children, or adolescents should be submitted to category (P).  

J HIV-Related Malignancies and Tumor Viruses  Studies of epidemiology, pathobiology, prognostic biomarkers, incidence, treatment, gynecologic malignancies, human papillomavirus screening, and prevention approaches for malignancies or premalignant lesions in patients with HIV infection. 
K Cardiovascular Complications of HIV Infection and Antiretroviral Therapy   Complications of HIV infection and antiretroviral therapy including coronary and cardiac complications, lipids, and peripheral vascular atheromatous disease. 

Cerebrovascular complications, including stroke, should be submitted to category (E). 

L Other Complications of HIV Infection and Antiretroviral Therapy in Adults   Studies of renal, bone, frailty, metabolic, and other complications (excluding neurologic or liver complications) in HIV. Neurologic complications should be submitted to category (E). Liver complications should be submitted to category (I). 
M Clinical Manifestations and Outcomes of SARS-CoV-2, Including Long COVID, and Mpox Infections Studies of clinical manifestations and co-morbidities associated with, and complications of, SARS-CoV-2 and mpox in adults. Includes acute COVID-19 disease and post-acute sequelae of COVID-19 (PASC, or long COVID). 

Neurologic complications of COVID-19 should be submitted to category (E). Studies of infants, children, or adolescents should be submitted to the categories (O) or (P). 

N Tuberculosis and Other Opportunistic Infections, Including the Impact of HIV or SARS-CoV-2 in Adults   Basic and clinical studies of bacterial, fungal, parasitic, mycobacterial, and non-hepatitis viral infections, including the impact of coinfections with SARS-CoV-2, tuberculosis, and other opportunistic infections. This category will also include integrated strategy studies that evaluate the effectiveness, safety, and acceptability of biomedical, behavioral, and structural interventions to treat or prevent coinfections and opportunistic infections in people with HIV.
O Maternal and Fetal HIV, SARS-CoV-2, and Mpox Virus Studies of maternal-fetal HIV, SARS-CoV-2, mpox, and their related infections: transmission, prevention, treatment, pregnancy, and postpartum maternal health. Includes: Mother-to-child transmission; approaches to diagnosis, prevention, and treatment of infections and co-morbidities during pregnancy and breastfeeding; possible risks associated with treatments in pregnancy and breastfeeding; issues of postpartum maternal health; and early infant diagnosis.
P Childhood and Adolescent HIV, SARS-CoV-2, or Mpox Virus Studies of the diagnosis, treatment, and management (including biomedical, behavioral, and structural interventions) of HIV and related co-infections and co-morbidities in infants, children, and young adults, including HIV-exposed uninfected infants and children. This category includes SARS-CoV-2 and mpox in these populations.
Epidemiology/Public Health
Q Epidemiology of HIV, COVID-19, and Mpox Studies of the incidence and prevalence of HIV, COVID-19, and mpox. Includes risk factors for acquisition or transmission; biomedical, behavioral, and structural determinants; morbidity and mortality; surveillance; transmission, including phylogenetics; molecular epidemiology; and studies focused on vulnerable populations.
R Testing for HIV, COVID-19, and Mpox in Adults: New Tests, Population Studies, and Scale-Up Studies evaluating the performance characteristics, implementation, and cost-effectiveness of diagnostics and related tests for HIV, COVID-19, and mpox. Includes community-, partner-, and self-testing; innovative approaches and technologies; scale-up of testing; and descriptive epidemiology of testing results.
S Prevention of HIV, COVID-19, and Mpox in Adults Preclinical and clinical studies of prevention strategies for HIV, COVID-19, and mpox. Includes microbicides, pre- and post-exposure prophylaxis, treatment as prevention, medical male circumcision, and other prevention interventions. Implementation of prevention strategies for HIV-uninfected populations, and studies in which HIV incidence is the primary outcome.

Studies of infants, children, and adolescents should be submitted to category (P); studies of pregnant and breastfeeding women should be submitted to category (O).

T Contraception, Sexually Transmitted Infections, and Reproductive Health in Adults Studies of sexually transmitted infections, contraception and reproductive health in women and men; includes studies of contraception and other aspects of sexual and reproductive health in populations with or at risk of HIV.

Studies on HIV epidemiology, prevention, and treatment in women and in infants, children, and adolescents should be included in their respective categories.

U Implementation and Scale-Up of Prevention and Treatment for HIV, and Impact of COVID-19 and Mpox on HIV-Related Programs   Studies of HIV prevention and treatment cascades, implementation science studies, experiences with scale-up of HIV prevention and treatment, and population-level impact of prevention and treatment on health outcomes of persons at risk for or with HIV. Includes integrated strategy studies that evaluate the implementation of biomedical, behavioral, and structural interventions; the impact of COVID-19 or mpox on HIV-related services (including impact on financing) are included.